Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients

NCT06665568 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Depressive Symptoms Mild to Moderate in Severity
Anxiety
Quality of Life (QOL)
Caregiver Burden
Sleep Quality

Interventions

DRUG: Intranasal ketamine hydrochloride

Sponsor

University of Zurich